Skip to Content
Merck

G3798

10074-G5

≥98% (HPLC)

Synonym(s):

Biphenyl-2-yl-(7-nitrobenzo[1,2,5]oxadiazol-4-yl)amine, N-2-Biphenylyl-7-nitro-2,1,3-benzoxadiazol-4-amine, N-[1,1′-Biphenyl-2-yl]-7-nitro-2,1,3-Benzoxadiazol-4-amine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H12N4O3
CAS Number:
413611-93-5
Molecular Weight:
332.31
NACRES:
NA.77
PubChem Substance ID:
329799918
UNSPSC Code:
12352200
MDL number:
MFCD00576774

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

KMJPYSQOCBYMCF-UHFFFAOYSA-N

SMILES string

[O-][N+](=O)c1ccc(Nc2ccccc2-c3ccccc3)c4nonc14

InChI

1S/C18H12N4O3/c23-22(24)16-11-10-15(17-18(16)21-25-20-17)19-14-9-5-4-8-13(14)12-6-2-1-3-7-12/h1-11,19H

assay

≥98% (HPLC)

form

powder

color

red

solubility

DMSO: >10 mg/mL

storage temp.

room temp

Quality Level

100

Related Categories

Biochem/physiol Actions

10074-G5 is a c-Myc/Max interaction inhibitor.
10074-G5 is a c-Myc/Max interaction inhibitor. The c-Myc oncoprotein and its partner Max are intrinsically disordered (ID) monomers that undergo coupled folding and binding upon heterodimerization. 10074-G5, similarly to 10058-F4 (#F3680), specifically inhibits this interaction by binding to c-Myc, thus preventing C-Myc specific DNA binding and target genes regulation. 10074-G5 (2.8 microM) is slightly more potent that 10058-F4 (5.2 microM). It was discovered that 10074-G5 binds to a different specific binding site (region) of C-Myc than 10054-F4. Thus, the compound may become desirable for probing different interactions.

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

G3798-BULK: + G3798-5MG: + G3798-25MG: + G3798-IP: + G3798-VAR:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000124785
0000124786
0000078958
0000078959
0000036685

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Philipp Raffeiner et al.
Oncotarget, 5(19), 8869-8878 (2014-10-20)
The oncogenic bHLH-LZ transcription factor Myc forms binary complexes with its binding partner Max. These and other bHLH-LZ-based protein-protein interactions (PPI) in the Myc-Max network are essential for the physiological and oncogenic activities of Myc. We have generated a genetically
Quan Yang et al.
Frontiers in immunology, 12, 627072-627072 (2021-03-13)
The accumulation of myeloid-derived suppressor cells (MDSCs) is one of the major obstacles to achieve an appropriate anti-tumor immune response and successful tumor immunotherapy. MDSCs in tumor-bearing hosts are primarily polymorphonuclear (PMN-MDSCs). However, the mechanisms regulating the development of MDSCs
Alina Castell et al.
Scientific reports, 8(1), 10064-10064 (2018-07-04)
MYC is a key player in tumor development, but unfortunately no specific MYC-targeting drugs are clinically available. MYC is strictly dependent on heterodimerization with MAX for transcription activation. Aiming at targeting this interaction, we identified MYCMI-6 in a cell-based protein
Udom Lao-On et al.
Biochimica et biophysica acta. Molecular basis of disease, 1866(3), 165656-165656 (2019-12-25)
Here we showed that the c-Myc oncogene is responsible for overexpression of pyruvate carboxylase (PC) in highly invasive MDA-MB-231 cells. Pharmacological inhibition of c-Myc activity with 10074-G5 compound, resulted in a marked reduction of PC mRNA and protein, concomitant with
Gabriella T Heller et al.
Science advances, 6(45) (2020-11-06)
Disordered proteins are challenging therapeutic targets, and no drug is currently in clinical use that modifies the properties of their monomeric states. Here, we identify a small molecule (10074-G5) capable of binding and sequestering the intrinsically disordered amyloid-β (Aβ) peptide
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service